Week in Review: WuXi PharmaTech Acquires XenoBiotic, a US-China CRO

WuXi PharmaTech acquired XenoBiotic Laboratories, a US-China pre-clinical CRO with specific expertise in radio-labeled compound studies; Fosun's offer of $584 million is the current high bid for Espirito Santo Saude, a Portuguese chain of hospitals clinics and nursing homes; Verisante Technology of Canada and an unnamed partner will establish a JV to hold China rights for its cancer detection technology; Sanofi opened an R&D hub in Shanghai that is tasked with managing the company's more than 50 research partnerships in China and 11 other Asia Pacific countries; Novotech, a pan-Asia clinical-stage CRO headquartered in Australia, opened its own Shanghai office; and US-based BSD Medical received CFDA approval for its hyperthermia device that treats cancer. More details.... Stock Symbols: (NYSE: WX) (HK: 656) (TSX: VRS; OTCQX: VRSEF) (NYSE: SNY) (NSDQ: BSDM) Share this with colleagues: // //